A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

Arthritis and Rheumatism
Dianne PetronePaul Dalgin

Abstract

To evaluate the safety and efficacy of 2 dosages of cevimeline for the treatment of xerostomia and keratoconjunctivitis sicca in patients with Sjögren's syndrome. A 12-week double-blind, randomized, placebo-controlled study was performed. Patients were randomly assigned to receive either placebo, 15 mg of cevimeline 3 times daily, or 30 mg of cevimeline 3 times daily. Patients were evaluated at baseline and throughout the study for their global assessment of dryness (mouth, eyes, overall) as well as their subjective assessment of the specific symptoms of dry mouth and dry eyes. Total saliva and tear flow also were measured. Patients taking 30 mg of cevimeline 3 times daily had statistically significant improvements in their subjective global assessment of dry eyes (P = 0.0453), dry mouth (P = 0.0004), and increased salivary flow (P = 0.007). Patients receiving the 30-mg dosage also showed greater objective improvement (increased salivary and lacrimal flow rates, as measured by Schirmer's test) than did patients receiving placebo. Frequently reported adverse events included headache, increased sweating, abdominal pain, and nausea. Treatment with cevimeline at a dosage of 30 mg 3 times daily resulted in substantive improvement by...Continue Reading

References

Feb 13, 1990·European Journal of Pharmacology·L MeiH I Yamamura
Feb 5, 1998·European Journal of Pharmacology·H MasunagaY Takeshita
Jul 16, 1999·Seminars in Arthritis and Rheumatism·J M Anaya, N Talal

❮ Previous
Next ❯

Citations

Dec 17, 2009·Zeitschrift für Rheumatologie·A Hansen, T Dörner
Apr 12, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Akiko MoritoYojiro Ota
Sep 23, 2010·Clinical Oral Investigations·Johannes K-H MeierUNKNOWN International Consensus Conference on Clinical Practice in cGVHD
Jan 16, 2007·Clinical Rheumatology·Hiroyuki YamadaIchiro Saito
Jun 22, 2005·Current Allergy and Asthma Reports·Michael Samarkos, Haralampos M Moutsopoulos
Nov 10, 2007·Clinical Reviews in Allergy & Immunology·Clio P Mavragani, Haralampos M Moutsopoulos
Sep 25, 2010·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Berenika VoskoboynikJason B Hack
Jan 24, 2013·Drugs & Aging·Rada V MoermanArjan Vissink
Aug 26, 2006·Nature Clinical Practice. Rheumatology·Clio P MavraganiHaralampos M Moutsopoulos
May 3, 2012·Nature Reviews. Rheumatology·Manuel Ramos-CasalsAthanasios G Tzioufas
Oct 10, 2009·Photomedicine and Laser Surgery·Alyne SimõesJose Nicolau
Sep 10, 2003·Current Opinion in Rheumatology·Arne HansenThomas Dörner
Aug 12, 2005·Current Opinion in Rheumatology·Arne HansenThomas Dörner
Oct 13, 2009·International Journal of Clinical Practice·V Visvanathan, P Nix
Oct 23, 2004·Annals of the Rheumatic Diseases·M Ramos-CasalsJ Font
Feb 15, 2005·Annals of the Rheumatic Diseases·B GescukJ C Davis
Sep 26, 2009·American Journal of Physiology. Gastrointestinal and Liver Physiology·Jagmohan SinghSatish Rattan
Feb 22, 2005·Pharmacology·Kimihiro SuzukiFumitaka Ohsuzu
Aug 7, 2008·Drugs·Juliane Weber, Gillian M Keating
Nov 24, 2004·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Noriyoshi OgawaSusumu Sugai
Mar 26, 2008·Journal of Dental Research·S A MathewsR H Scofield
Jan 8, 2014·Current Allergy and Asthma Reports·Katy C LiuRichard M Davis
Sep 10, 2014·Journal of Ophthalmology·Anushree Sharma, Holly B Hindman
Jul 13, 2007·Clinical Oral Investigations·Alyne SimõesNorbert Gutknecht
Jan 1, 2007·Women's Health·Ibtisam Al-Hashimi
Sep 8, 2010·Der Internist·A Hansen, T Dörner
Jan 31, 2003·Expert Opinion on Investigational Drugs·Robert I Fox
Jan 11, 2011·Expert Opinion on Pharmacotherapy·Murat Dogru, Kazuo Tsubota
Jan 26, 2016·Expert Opinion on Drug Safety·Jolien F van NimwegenArjan Vissink
Sep 11, 2007·Journal of Oral Rehabilitation·H Mese, R Matsuo
Aug 25, 2006·Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry·Nita Chainani-WuSol Silverman
Sep 19, 2006·Best Practice & Research. Clinical Rheumatology·P J Venables
Aug 2, 2014·Clinical Reviews in Allergy & Immunology·Valéria ValimRubens Belfort
Sep 12, 2015·Revista brasileira de reumatologia·Valéria ValimWanderley Marques Bernardo
Aug 29, 2003·Expert Opinion on Pharmacotherapy·Samuel E Taylor
Dec 1, 2003·Modern Rheumatology·Shingo NakayamadaYoshiya Tanaka
Jul 29, 2015·Seminars in Arthritis and Rheumatism·Coziana CiurtinDavid A Isenberg
Jul 15, 2016·Nature Reviews. Rheumatology·Alain SarauxValérie Devauchelle-Pensec
Dec 18, 2007·Auris, Nasus, Larynx·T NinM Sakagami
Apr 20, 2004·The Journal of Emergency Medicine·Robert G HendricksonMichael I Greenberg
May 30, 2015·Reumatología clinica·Rosa María López-PintorGonzalo Hernández
Nov 30, 2013·Oral and Maxillofacial Surgery Clinics of North America·Andres Pinto
Apr 5, 2011·Ophthalmology·Esen Karamursel AkpekPeter J McDonnell

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.